Increased levels of BLyS and sVCAM-1 in anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitides (AAV)

Clinical and Experimental Rheumatology

Volumn 28, Issue 1 SUPPL. 57, 2010, Pages

  Schneeweis, Christopher ^a,b   Rafalowicz, Michael ^b   Feist, Eugen ^b   Buttgereit, Frank ^b   Rudolph, Paul E ^c   Burmester, Gerd R ^b   Egerer, Karl ^b  

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c LEIBNIZ INSTITUTE FOR FARM ANIMAL BIOLOGY FBN   (Germany)

Author keywords

Anti neutrophil antibodies (ANCA) associated vasculitides (AAV); B lymphocyte stimulator (BLyS); sE Selectin; sVCAM 1

Indexed keywords

B CELL ACTIVATING FACTOR; C REACTIVE PROTEIN; CREATININE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; NEUTROPHIL CYTOPLASMIC ANTIBODY; VASCULAR CELL ADHESION MOLECULE 1; BIOLOGICAL MARKER; TNFSF13B PROTEIN, HUMAN; SOLUBLE VASCULAR CELL ADHESION MOLECULE 1; UNCLASSIFIED DRUG;

ADULT; AGED; ANCA ASSOCIATED VASCULITIS; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL ACTIVATION; CHURG STRAUSS SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MALE; MICROSCOPIC POLYANGIITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; WEGENER GRANULOMATOSIS; B LYMPHOCYTE; BLOOD; IMMUNOLOGY; METABOLISM; SIGNAL TRANSDUCTION; SOLUBILITY; ANTIBODY TITER; MAJOR CLINICAL STUDY;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; BIOLOGICAL MARKERS; E-SELECTIN; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FOLLOW-UP STUDIES; HUMANS; SIGNAL TRANSDUCTION; SOLUBILITY; VASCULAR CELL ADHESION MOLECULE-1;

EID: 77954599011     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. JENNETTE JC, FALK RJ, ANDRASSY K et al.: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-92.
2. WATTS RA, SCOTT DG: Classification and epidemiology of the vasculitides. Baillieres Clin Rheumatol 1997; 11: 191-217.
3. PHILLIP R, LUQMANI R: Mortality in systemic vasculitis: a systematic review. Clin Exp Rheumatol 2008; 26: S94-104.
4. CHEN M, KALLENBERG CG: New advances in the pathogenesis of ANCA-associated vasculitides. Clin Exp Rheumatol 2009; 27: S108-114.
5. FALK RJ, JENNETTE JC: Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 1988; 318: 1651-17.
6. JENNETTE JC, HOIDAL JR, FALK RJ: Specificity of anti-neutrophil cytoplasmic autoantibodies for proteinase 3. Blood 1990; 75: 2263-4.
7. XIAO H, SCHREIBER A, HEERINGA P, FALK RJ, JENNETTE JC: Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol 2007; 170: 52-64.
8. RADFORD DJ, SAVAGE CO, NASH GB: Treatment of rolling neutrophils with antineutrophil cytoplasmic antibodies causes conversion to firm integrin-mediated adhesion. Arthritis Rheum 2000; 43: 1337-45.
9. RADFORD DJ, LUU NT, HEWINS P, NASH GB, SAVAGE CO: Antineutrophil cytoplasmic antibodies stabilize adhesion and promote migration of flowing neutrophils on endothelial cells. Arthritis Rheum 2001; 44: 2851-61.
10. BOSCH X, GUILABERT A, FONT J: Anti-neutrophil cytoplasmic antibodies. Lancet 2006; 368: 404-18.
11. EWERT BH, JENNETTE JC, FALK RJ: Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. Kidney Int 1992; 41: 375-83.
12. LITTLE MA, SAVAGE CO: The role of the endothelium in systemic small vessel vasculitis. Clin Exp Rheumatol 2008; 26: S135-140.
13. SCHNEIDER P, MACKAY F, STEINER V et al.: BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999; 189: 1747-56.
14. SCAPINI P, NARDELLI B, NADALI G et al.: G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J Exp Med 2003; 197: 297-302.
15. MOORE PA, BELVEDERE O, ORR A et al.: BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999; 285: 260-3.
16. WOODLAND RT, SCHMIDT MR, THOMPSON CB: BLyS and B cell homeostasis. Semin Immunol 2006; 18: 318-26.
17. DO RK, CHEN-KIANG S: Mechanism of BLyS action in B cell immunity. Cytokine Growth Factor Rev 2002; 13: 19-25.
18. SEYLER TM, PARK YW, TAKEMURA S et al.: BLyS and APRIL in rheumatoid arthritis. J Clin Invest 2005; 115: 3083-92.
19. MACKAY F, SIERRO F, GREY ST, GORDON TP: The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr Dir Autoimmun 2005; 8: 243-65.
20. GROOM J, KALLED SL, CUTLER AH et al.: Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest 2002; 109: 59-68.
21. ZHANG J, ROSCHKE V, BAKER KP et al.: Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001; 166: 6-10.
22. CHEEMA GS, ROSCHKE V, HILBERT DM, STOHL W: Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001; 44: 1313-9.
23. EGERER K, FEIST E, ROHR U, PRUSS A, BURMESTER GR, DORNER T: Increased serum soluble CD14, ICAM-1 and E-selectin correlate with disease activity and prognosis in systemic lupus erythematosus. Lupus 2000; 9: 614-21.
24. EGERER K, HERTZER J, FEIST E et al.: sE-selectin for stratifying outcome in rheumatoid arthritis. Arthritis Rheum 2003; 49: 546-8.
25. ARA J, MIRAPEIX E, ARRIZABALAGA P et al: Circulating soluble adhesion molecules in ANCA-associated vasculitis. Nephrol Dial Transplant 2001; 16: 276-85.
26. HUNDER GG, AREND WP, BLOCH DA et al.: The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis Rheum 1990; 33: 1065-7.
27. FRIES JF, HUNDER GG, BLOCH DA et al.: The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum 1990; 33: 1135-6.
28. APLIN AE, HOWE A, ALAHARI SK, JULIANO RL: Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacol Rev 1998; 50: 197-263.
29. CARLOS TM, SCHWARTZ BR, KOVACH NL et al.: Vascular cell adhesion molecule-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells. Blood 1990; 76: 965-70.
30. STEGEMAN CA, TERVAERT JW, HUITEMA MG, DE JONG PE, KALLENBERG CG: Serum levels of soluble adhesion molecules intercellular adhesion molecule 1, vascular cell adhesion molecule 1, and E-selectin in patients with Wegener's granulomatosis. Relationship to disease activity and relevance during followup. Arthritis Rheum 1994; 37: 1228-35.
31. ARRIZABALAGA P, SOLE M, ABELLANA R, ASCASO C: Renal expression of adhesion molecules in anca-associated disease. J Clin Immunol 2008; 28: 411-9.
32. KRUMBHOLZ M, SPECKS U, WICK M, KALLED SL, JENNE D, MEINL E: BAFF is elevated in serum of patients with Wegener's granulomatosis. J Autoimmun 2005; 25: 298-302.
33. STOHL W, METYAS S, TAN SM et al.: B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003; 48: 3475-86.
34. ROCCATELLO D, BALDOVINO S, ALPA M et ai: Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement. Clin Exp Rheumatol 2008; 26: S67-71.